Published on 23 Feb 2024 on Simply Wall St. via Yahoo Finance
It's been a good week for Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders, because the company has just released its latest full-year results, and the shares gained 8.6% to US$23.98. Revenues of US$27m came in 9.7% below estimates, but statutory losses were slightly better than expected, at US$5.08 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
See our latest analysis for Bicycle Therapeutics
earnings-and-revenue-growth